Managing accelerating autoimmune drugs costs across benefits is critical
Prime’s pharmacist researchers studied integrated trends in autoimmune drug use and spend, and presented their findings at the Academy of Managed Care Pharmacy (AMCP) 2016 Nexus event. Get the highlights — and learn what plan sponsors can do.
Nov. 11, 2016 | Prime Therapeutics
Infographic: Drug pipeline profile: Duchenne muscular dystrophy
New therapies for this rare disease are in pipeline, and they could have a big impact on drug costs — up to $4.57 per member per year.
Aug. 31, 2016 | Patrick Gleason, PharmD, FCCP, BCPS
Prime research decodes top Stars-related adherence predictors by category
Prime explores the top predictors of future adherence for three key Star ratings drug categories — high blood pressure, high cholesterol and diabetes — based on a recent study of more than 1.1 million Medicare members.
Aug. 24, 2016 | Patrick Gleason, PharmD, FCCP, BCPS
Can big data help boost medicine-related Star ratings?
Prime performs adherence predictive modeling, using big data, to provide evidence-based recommendations to drive higher ratings for Star-related drug categories.
Aug. 2 2016 | Jonathan Gavras, MD, FCCP
The CREATES Act: A viable solution for more affordable prescription drug choices
Lawmakers are fighting for more affordable prescription drug choices for families. The CREATES Act can pave the way, and Prime Therapeutics is on board.
July 20, 2016 | Cathy Starner, PharmD, BCPS
America’s opioid epidemic: Part 5 — the future of safer opioid use
The opioid crisis is staggering, but steps are being taken in the right direction. What will tomorrow hold for safer opioid use?